The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASH 2015 | The promise of second-generation PI3K inhibitors for CLL

Name: The promise of second-generation PI3K inhibitors for CLL
Uploaded: 2015-12-04T00:00:00.000Z
Duration: 1 min 34 s
Description: At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc and Stephan Stilgenbauer, MD, explain the clinical development of second-generation phosphoinositide 3-kinase (PI3K) inhibitors, including duvelisib, which inhibits the delta and gamma isoforms of PI3K, and TGR-1202, which inhibits the delta isoform of PI3K.

John Gribben and Stephan Stilgenbauer • 4 Dec 2015

ASH 2015

Chronic Lymphocytic Leukemia Duvelisib

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc and Stephan Stilgenbauer, MD, explain the clinical development of second-generation phosphoinositide 3-kinase (PI3K) inhibitors, including duvelisib, which inhibits the delta and gamma isoforms of PI3K, and TGR-1202, which inhibits the delta isoform of PI3K.